Abigail Brooks, MA

Obesity rates in the US have skyrocketed, and so has the prevalence of several comorbid gastrointestinal and hepatic diseases - not all patients know their risks or have the financial means to take preventative measures.

Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Parents in the active disease group indicated greater levels of anxiety than parents of children without active IBD, suggesting a correlation between parental mental health and their child’s disease activity.

Patients aged less than 45 years at NAFLD onset had a higher risk of cancer compared to older age groups, highlighting an association between younger age at NAFLD onset and cancer risk.

Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.

Findings from a meta-analysis are calling attention to the viability of classification and risk stratification using greater albuminuria and decreased eGFR.

Among a cohort of young patients with no major comorbidity burdens, 49% were not waitlisted within 5 years of dialysis initiation.

Results showed a significant improvement in patient-reported physical well-being after 12 weeks of treatment with sofosbuvir/velpatasvir.

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production.

More than 90% of patients with CDI treated with WMT achieved clinical cure, while only 3.8% of WMTs resulted in adverse events.

Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990-2019.

Data from the VISIBLE 1 trial showed more patients receiving subcutaneous vedolizumab achieved clinical remission, mucosal healing, durable clinical response, durable clinical remission, and corticosteroid-free clinical remission compared to those receiving placebo.

Results from the systematic review and meta-analysis showed FMT restored the normal microbiome, reduced the risk of gastrointestinal infections, and did not lead to increased adverse events in patients with HIV.

Findings revealed more than 5,000 excess deaths from CDI and 35.6% excess risk compared to the expected number of disease deaths calculated using data from the National Vital Statistics System.

Nearly 95% of patients with HCV treated with DAA therapy achieved SVR, regardless of alcohol consumption.

Results from EoE KIDS showed 68% of patients on a higher dose of dupilumab and 58% of patients on a lower dose achieved significant histological disease remission.

Participants indicated multiple factors affected their decision to contact out-of-hours primary care for their child with gastroenteritis and detailed areas of disconnect between their expectations and actions taken by the general practitioner.

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.

The presence of NAFLD increased from 25.3% to 29.4% among patients receiving oral menopause hormone therapy.

Results from both studies showed the safety of filgotinib for the treatment of ulcerative colitis compared to placebo treatment groups.

Investigators suggested an ALT/HDL-C ratio of 15.97 as a screening threshold for identifying NAFLD, noting its increased effectiveness compared to ALT, HDL-C, the aspartate aminotransferase to HDL-C ratio, and the gamma-glutamyl transferase to HDL-C ratio.

Results showed increased liver stiffness measured by vibration-controlled transient elastography was associated with all-cause mortality in patients with NAFLD.

Nearly half of patients with IBD in remission experienced abdominal pain, which was associated with sex, fatigue, and depressive symptoms.

Although intervention increased HCV RNA testing compared to patients in the standard of care group, treatment uptake was unaffected.

More patients who retransitioned to originator infliximab after switching to a biosimilar discontinued infliximab than patients who remained on the biosimilar.

The greatest level of treatment discontinuation was seen among patients aged 18-24 years, highlighting an increased risk of early disease relapse.

Increased physical activity and diet quality were associated with a lower risk of all-cause and cardiovascular disease-related mortality among patients with NAFLD.

Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.

Jordan Baeker Bispo, PhD, MPH, discusses the importance of colorectal cancer screening, why clinician screening recommendations are so important, and how patient-clinician communication gaps should be addressed.